Affitope AD 02

Drug Profile

Affitope AD 02

Alternative Names: AD-02; AD-2; Affitope AD02; Alzheimer AD02

Latest Information Update: 03 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AFFiRiS
  • Class Alzheimer vaccines; Subunit vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 23 Jun 2014 Discontinued - Phase-II for Alzheimer's disease in Austria, Germany, France, Croatia, Czech Republic and Slovakia (SC)
  • 05 Jun 2014 Efficacy and adverse events data from a phase II trial in Alzheimer's disease (early disease) released by AFFiRiS
  • 01 Dec 2013 AFFiRiS completes a phase II trial in Alzheimer's disease in Austria, Croatia, Czech Republic, France, Germany, and Slovakia (NCT01117818)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top